Drug Trial Radar · NCT06873854
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Mar 26, 2025
Primary completion
Jan 26, 2028
Study completion Jan 26, 2030
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- First posted
- Mar 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Based on overall response rate (ORR) as assessed by the Independent Review Committee (IRC) against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria for Solid Tumor Efficacy, To evaluate the efficacy of LM-108 in combination with Toripalimab in patients with advanced malignant solid tumours with unresectable or metastatic MSI-H/dMMR who have failed previous anti-PD-1 /PD-L1 therapy.
Conditions
- Advanced Solid Tumor
Interventions
LM-108Drug
Q3W, Intravenous Drip
ToripalimabDrug
Q3W, Intravenous Drip
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 104 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.